Canopy Growth (CGC) Other Non Operating Income (2019 - 2025)
Canopy Growth (CGC) reported Other Non Operating Income of -$29.7 million for Q4 2025, up 43.86% on a YoY basis from -$20.7 million in Q4 2024, and down 437.17% sequentially from $8.8 million in Q3 2025.
Canopy Growth (CGC) Other Non Operating Income (2019 - 2025) Analysis & Trends
Canopy Growth (CGC) has 7 years of Other Non Operating Income data on file, last reported at -$29.7 million in Q4 2025.
- For the quarter ending Q4 2025, Other Non Operating Income rose 43.86% year-over-year to -$29.7 million; the trailing twelve-month figure through Dec 2025 stood at -$89.7 million (down 598.01% YoY), and the FY2026 full-year result was -$1.1 million, up 99.59% from the prior year.
- Other Non Operating Income slipped to -$29.7 million in Q4 2025, from $8.8 million in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $172.4 million in Q1 2024 to a low of -$646.8 million in Q1 2022.
- A 5-year average of -$52.0 million and a median of -$15.8 million in 2025 frame the typical range for Other Non Operating Income.
- Across the five-year window, Other Non Operating Income slumped 141034.7% in 2022 and soared 8409.42% in 2024, its largest moves.
- Tracing CGC's Other Non Operating Income over 5 years: stood at $785402.7 in 2021, then sank by 10932.89% to -$85.1 million in 2022, then plunged by 38.05% to -$117.5 million in 2023, then jumped by 54.93% to -$52.9 million in 2024, then soared by 43.86% to -$29.7 million in 2025.
- Business Quant data shows CGC's Other Non Operating Income at -$29.7 million in Q4 2025, $8.8 million in Q3 2025, and -$15.8 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Canopy Growth | 197.77 Mn | -68.15 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -29.72 Mn |
| Sep 30, 2025 | 8.81 Mn |
| Jun 30, 2025 | -15.84 Mn |
| Dec 31, 2024 | -52.93 Mn |
| Sep 30, 2024 | -48.36 Mn |
| Jun 30, 2024 | -53.10 Mn |
| Mar 31, 2024 | 172.40 Mn |
| Dec 31, 2023 | -117.46 Mn |
| Sep 30, 2023 | -89.30 Mn |
| Jun 30, 2023 | -103,478.89 |
| Mar 31, 2023 | 2.03 Mn |
| Dec 31, 2022 | -85.08 Mn |
| Sep 30, 2022 | -29.96 Mn |
| Jun 30, 2022 | -3.87 Mn |
| Mar 31, 2022 | -646.76 Mn |
| Dec 31, 2021 | 785,402.72 |
| Sep 30, 2021 | 700,669.01 |
| Jun 30, 2021 | 837,932.97 |
| Mar 31, 2021 | -458,257.49 |
| Dec 31, 2020 | 544,608.81 |